Export

You can select particular sections to be included in the output file.
EN
FR

Model List of Essential Medicines

clear Found 327 recommendations for 94 medicines and 24 therapeutic equivalents
Removed medicines and rejected applications are not shown. Show them.
8.2. Antineoplastics and supportive medicines
  1. Abiraterone General information
    Section
    Hormones and antihormones
    • Oral > Solid: 250 mg; 500 mg
    Indications
    Malignant neoplasms of prostate
  2. Afatinib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung
  3. All-trans retinoic acid General information
    Section
    Targeted therapies
    • Oral > Solid: 10 mg capsule
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities
  4. Allopurinol General information
    Section
    Supportive medicines
    • Parenteral > General injections > IV: 500 mg (as sodium) powder for injection
    • Oral > Solid: 100 mg; 300 mg
    Indications
    Tumour lysis syndrome
  5. Anastrozole General information
    Section
    Hormones and antihormones
    • Oral > Solid: 1 mg tablet
    Indications
    Malignant neoplasms of breast Other specified malignant neoplasms of breast
  6. Arsenic trioxide General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities
  7. Asparaginase General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 10000 IU in vial powder for injection
    Indications
    Lymphoid leukaemia, not elsewhere classified
  8. Atezolizumab General information
    Section
    Immunomodulators
    Indications
    Therapeutic equivalent to pembrolizumab for Other specified malignant neoplasms of bronchus or lung
  9. Bendamustine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL
    Indications
    Chronic lymphocytic leukaemia or small lymphocytic lymphoma Follicular lymphoma
  10. Bicalutamide General information
    Section
    Hormones and antihormones
    • Oral > Solid: 50 mg
    Indications
    Malignant neoplasms of prostate
  11. Bleomycin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)
    Indications
    Kaposi sarcoma of unspecified primary site Germ cell tumour of testis Other specified malignant neoplasms of the ovary Hodgkin lymphoma
  12. Blinatumomab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 35 µg in vial; 38.5 µg in vial
    Indications
    B lymphoblastic leukaemia or lymphoma, not elsewhere classified
  13. Bortezomib General information
    Section
    Targeted therapies
    • Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection
    Indications
    Plasma cell myeloma
  14. Calcium folinate (leucovorin calcium) General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule; 7.5 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
    • Oral > Solid > tablet: 15 mg; 5 mg; 25 mg
    Indications
    Burkitt lymphoma including Burkitt leukaemia Osteosarcoma of bone or articular cartilage of unspecified sites Malignant neoplasms of rectum Malignant neoplasm metastasis in large intestine Malignant neoplasms of colon Malignant trophoblastic neoplasms of placenta
  16. Carboplatin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL
    Indications
    Other specified gliomas of brain Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx Malignant neoplasms of cervix uteri Malignant neoplasms of hypopharynx Malignant neoplasms of nasopharynx Malignant neoplasms of oropharynx Osteosarcoma of bone or articular cartilage of unspecified sites Other specified malignant neoplasms of the ovary Germ cell tumour of testis Malignant neoplasms of nasopharynx Other specified carcinomas of ovary Other specified malignant neoplasms of bronchus or lung Malignant neoplasms of breast Retinoblastoma Malignant neoplasms of kidney, except renal pelvis
  17. Cemiplimab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 50 mg per mL in 7 mL vial concentrate for solution for infusion
    Indications
    Therapeutic equivalent to pembrolizumab for Other specified malignant neoplasms of bronchus or lung Other specified malignant neoplasms of bronchus or lung
  18. Chlorambucil General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 2 mg tablet
    Indications
    Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  20. Cyclophosphamide General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
    • Oral > Solid > dosage form: 25 mg; 50 mg
    Indications
    Diffuse large B-cell lymphoma, not otherwise specified Chronic lymphocytic leukaemia or small lymphocytic lymphoma Plasma cell myeloma Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, not elsewhere classified Other specified gliomas of brain Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Rhabdomyosarcoma primary site Malignant neoplasms of breast Other specified malignant neoplasms of breast Hodgkin lymphoma Malignant trophoblastic neoplasms of placenta Follicular lymphoma Ewing sarcoma of bone or articular cartilage of unspecified sites Malignant neoplasms of kidney, except renal pelvis
  22. Dacarbazine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection
    Indications
    Hodgkin lymphoma
  24. Dasatinib General information
    Section
    Targeted therapies
    • Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet
    Indications
    Chronic myelogenous leukaemia, BCR-ABL1-positive
  25. Daunorubicin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities Lymphoid leukaemia, not elsewhere classified Myeloid leukaemia
  26. Dexamethasone General information
    Section
    Hormones and antihormones
    • Oral > Liquid: 2 mg per 5 mL
    • Oral > Solid: 2 mg; 4 mg
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosophate salt)
    • Oral > Liquid: 2 mg per 5 mL (as sodium phosphate)
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)
    • Oral > Solid > tablet: 2 mg (as dexamethasone base); 4 mg (as dexamethasone base)
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base
    • Oral > Solid > tablet: 4 mg (as dexamethasone base)
    Indications
    Anaplastic large cell lymphoma, ALK-negative Lymphoid leukaemia, not elsewhere classified Plasma cell myeloma Burkitt lymphoma including Burkitt leukaemia Anaplastic large cell lymphoma, ALK-positive
  27. Docetaxel General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL
    Indications
    Malignant neoplasms of breast Other specified malignant neoplasms of breast Malignant neoplasms of prostate
  28. Doxorubicin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection; 50 mg in vial (hydrochloride) powder for injection; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)
    Indications
    Diffuse large B-cell lymphoma, not otherwise specified Plasma cell myeloma Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, not elsewhere classified Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Osteosarcoma of bone or articular cartilage of unspecified sites Kaposi sarcoma of unspecified primary site Malignant neoplasms of breast Other specified malignant neoplasms of breast Hodgkin lymphoma Follicular lymphoma Ewing sarcoma of bone or articular cartilage of unspecified sites Malignant neoplasms of kidney, except renal pelvis
  29. Doxorubicin (as pegylated liposomal) General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 2 mg per mL in 10 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)
    Indications
    Kaposi sarcoma of unspecified primary site
  30. Enzalutamide General information
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to abiraterone for Malignant neoplasms of prostate
  31. Erlotinib General information
    Section
    Targeted therapies
    • Oral > Solid: 100 mg; 150 mg
    Indications
    Other specified malignant neoplasms of bronchus or lung
  32. Etoposide General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
    • Oral > Solid: 100 mg capsule; 50 mg capsule
    Indications
    Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, not elsewhere classified Myeloid leukaemia Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Germ cell tumour of testis Osteosarcoma of bone or articular cartilage of unspecified sites Other specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Hodgkin lymphoma Malignant trophoblastic neoplasms of placenta Retinoblastoma Ewing sarcoma of bone or articular cartilage of unspecified sites Malignant neoplasms of kidney, except renal pelvis
  33. Everolimus General information
    Section
    Targeted therapies
    • Oral > Solid > dispersible tablet: 2 mg; 3 mg; 5 mg
    • Oral > Solid > tablet: 2.5 mg; 5 mg; 7.5 mg; 10 mg
    Indications
    Other specified gliomas of brain
  34. Filgrastim General information
    Section
    Immunomodulators
    • Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial
    Indications
    Acquired neutropaenia
  35. Fludarabine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection
    • Oral > Solid: 10 mg tablet (fludarabine phosphate)
    Indications
    Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  37. Flutamide General information
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to bicalutamide for Malignant neoplasms of prostate
  38. Gefitinib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung
  39. Gemcitabine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection
    Indications
    Other specified carcinomas of ovary Other specified malignant neoplasms of bronchus or lung
  40. Goserelin General information
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to leuprorelin for Malignant neoplasms of breast Therapeutic equivalent to leuprorelin for Malignant neoplasms of prostate
  41. Hydrocortisone General information
    Section
    Hormones and antihormones
    • Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)
    Indications
    Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia
  42. Hydroxyurea (hydroxycarbamide) General information
    Section
    Cytotoxic medicines
    • Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg
    Indications
    Chronic myeloid leukaemia, not elsewhere classified
  43. Ibrutinib General information
    Section
    Targeted therapies
    • Oral > Solid: 140 mg
    Indications
    Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  46. Irinotecan General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial
    Indications
    Rhabdomyosarcoma primary site Malignant neoplasm metastasis in large intestine Malignant neoplasms of kidney, except renal pelvis
  47. Lenalidomide General information
    Section
    Immunomodulators
    • Oral > Solid: 25 mg
    Indications
    Plasma cell myeloma
  48. Leuprorelin General information
    Section
    Hormones and antihormones
    • Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe
    Indications
    Malignant neoplasms of breast Malignant neoplasms of prostate
  49. Melphalan General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection
    • Oral > Solid: 2 mg
    Indications
    Plasma cell myeloma
  50. Mercaptopurine General information
    Section
    Cytotoxic medicines
    • Oral > Liquid: 20 mg per mL
    • Oral > Solid: 50 mg tablet
    Indications
    Lymphoid leukaemia, not elsewhere classified Acute myeloid leukaemia with recurrent genetic abnormalities Langerhans cell histiocytosis
  51. Mesna General information
    Section
    Supportive medicines
    • Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 2 mL ampoule
    • Oral > Solid > tablet: 400 mg; 600 mg
    • Oral > Other: 600 mg
    • Oral > Solid > tablet: 400 mg
    Indications
    Rhabdomyosarcoma primary site Germ cell tumour of testis Other specified malignant neoplasms of the ovary Osteosarcoma of bone or articular cartilage of unspecified sites Ewing sarcoma of bone or articular cartilage of unspecified sites Malignant neoplasms of kidney, except renal pelvis Burkitt lymphoma including Burkitt leukaemia
  53. Methylprednisolone General information
    Section
    Hormones and antihormones
    • Parenteral > General injections > IV: 40 mg in vial (as sodium succinate); 125 mg in vial (as sodium succinate)
    • Parenteral > General injections > IV: 40 mg in vial (as sodium succinate) powder for injection; 125 mg in vial (as sodium succinate) powder for injection
    Indications
    Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, not elsewhere classified
  54. Nilotinib General information
    Section
    Targeted therapies
    • Oral > Solid > capsule: 150 mg; 200 mg
    Indications
    Chronic myelogenous leukaemia, BCR-ABL1-positive
  55. Nilutamide General information
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to bicalutamide for Malignant neoplasms of prostate
  56. Nivolumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion
    • Parenteral > General injections > IV: 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion; 10 mg per mL in 24 mL vial concentrate solution for infusion
    Indications
    Therapeutic equivalent to pembrolizumab for Melanoma of skin Melanoma of skin
  57. Oxaliplatin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial
    Indications
    Malignant neoplasm metastasis in large intestine Malignant neoplasms of colon
  59. Pegaspargase General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection
    Indications
    Lymphoid leukaemia, not elsewhere classified
  60. Pegfilgrastim General information
    Section
    Immunomodulators
    • Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe
    Indications
    Acquired neutropaenia
  61. Pembrolizumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 25 mg per mL in 4 mL vial
    • Parenteral > General injections > IV: 25 mg per mL in 4 mL vial powder for injection
    Indications
    Melanoma of skin Other specified malignant neoplasms of large intestine Malignant neoplasms of cervix uteri Therapeutic equivalent to nivolumab for Melanoma of skin Other specified malignant neoplasms of bronchus or lung
  63. Prednisone General information
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to prednisolone for Lymphoid leukaemia, not elsewhere classified Therapeutic equivalent to prednisolone for Diffuse large B-cell lymphoma, not otherwise specified Therapeutic equivalent to prednisolone for Chronic lymphocytic leukaemia or small lymphocytic lymphoma Therapeutic equivalent to prednisolone for Plasma cell myeloma Therapeutic equivalent to prednisolone for Anaplastic large cell lymphoma, ALK-negative Therapeutic equivalent to prednisolone for Anaplastic large cell lymphoma, ALK-positive Therapeutic equivalent to prednisolone for Langerhans cell histiocytosis Therapeutic equivalent to prednisolone for Hodgkin lymphoma Therapeutic equivalent to prednisolone for Malignant neoplasms of prostate Therapeutic equivalent to prednisolone for Follicular lymphoma
  64. Procarbazine General information
    Section
    Cytotoxic medicines
    • Oral > Solid > capsule: 50 mg (as hydrochloride)
    Indications
    Hodgkin lymphoma
  65. Rasburicase General information
    Section
    Supportive medicines
    • Parenteral > General injections > IV: 1.5 mg in vial powder and 1 mL solvent for solution; 7.5 mg in vial powder and 5 mL solvent for solution
    Indications
    Tumour lysis syndrome
  66. Realgar-indigo naturalis formulation General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities
  67. Rituximab General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial
    Indications
    Diffuse large B-cell lymphoma, not otherwise specified Chronic lymphocytic leukaemia or small lymphocytic lymphoma Burkitt lymphoma including Burkitt leukaemia Follicular lymphoma
  68. Tamoxifen General information
    Section
    Hormones and antihormones
    • Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)
    Indications
    Malignant neoplasms of breast Other specified malignant neoplasms of breast
  69. Thalidomide General information
    Section
    Immunomodulators
    • Oral > Solid: 50 mg
    Indications
    Plasma cell myeloma
  70. Tioguanine General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 40 mg
    Indications
    Lymphoid leukaemia, not elsewhere classified
  71. Trastuzumab General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection
    Indications
    Carcinoma of breast, specialised type
  72. Triptorelin General information
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to leuprorelin for Malignant neoplasms of breast Therapeutic equivalent to leuprorelin for Malignant neoplasms of prostate
  75. Vinorelbine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial
    • Oral > Solid > capsule: 20 mg; 30 mg; 80 mg
    • Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial
    Indications
    Rhabdomyosarcoma primary site Other specified malignant neoplasms of bronchus or lung Other specified malignant neoplasms of breast
  76. Zanubrutinib General information
    Section
    Targeted therapies
    • Oral > Solid > capsule: 80 mg
    Indications
    Therapeutic equivalent to ibrutinib for Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  77. Zoledronic acid General information
    Section
    Supportive medicines
    • Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle
    Indications
    Malignant neoplasm metastasis in bone or bone marrow